April 28, 2017: Strong sales from three drugs propelled BMS to a stronger-than-expected first quarter, which may have whet the appetites of companies considering making a move to acquire the pharma giant.
April 28, 2017: In a move that surprised almost everyone, Edward Kaye, president, CEO and director of the board of Sarepta announced yesterday that he would be leaving the company when his term ends on September 20, 2017.
April 28, 2017: Amgen has demonstrated a pretty good track record of beating Wall Street earnings estimates. The big biotech kept the streak going when it announced first-quarter results on Wednesday after the market closed.
April 28, 2017: Fresh off the heels of a deal with Biogen worth up to half-a-billion dollars, BMS has opted to not exercise its option to acquire U.K.-based F - star Alpha. In BMS’ quarterly filing with the SEC, the company said it opted against the option.